ExchangeDEX+
Buy CryptoMarketsSpotFuturesGOLDEarnEvent Center
More
ICP Zero-Fee Gala
GOTHENBURG, Sweden and LONDON, Jan. 23, 2026 /PRNewswire/ — Atley Solutions and Perceptive Discovery today announced the sale of two Atley C100 modules to PerceptiveGOTHENBURG, Sweden and LONDON, Jan. 23, 2026 /PRNewswire/ — Atley Solutions and Perceptive Discovery today announced the sale of two Atley C100 modules to Perceptive

ATLEY AND PERCEPTIVE ANNOUNCE STRATEGIC COLLABORATION FOCUSED ON ASTATINE-211

Author: AI JournalSource: AI Journal
2026/01/23 22:34
4 min read

GOTHENBURG, Sweden and LONDON, Jan. 23, 2026 /PRNewswire/ — Atley Solutions and Perceptive Discovery today announced the sale of two Atley C100 modules to Perceptive Discovery, marking the first step in a strategic collaboration aimed at establishing robust capabilities for drug development with astatine-211 (At-211). The two installations represent major milestones for both companies, as well as for the At-211 field as a whole.

One Atley C100 module will be installed at Perceptive Discovery’s laboratory in Needham, MA, marking the first-ever installation of the technology at a commercial CRO in the United States. The second unit will be installed at Perceptive Discovery’s partner laboratory at Queen Mary University of London, representing the first installation of the Atley C100 in the United Kingdom.

A Collaboration to Expand Global Access to At-211 Radiopharmaceutical Development
The sale of the two Atley C100 modules marks the beginning of a long-term strategic partnership between Atley and Perceptive Discovery, focused on enabling the next generation of targeted alpha therapy. Together, the companies will combine advanced equipment, specialized services, and deep technical expertise to accelerate the discovery and development of radiopharmaceutical candidates based on At-211.

As the world’s first and only automated manufacturing module purpose-built for At-211 radiopharmaceuticals, the Atley C100 delivers standardized, reproducible, and scalable manufacturing with a high degree of operator protection. With two systems deployed across the US and UK, Perceptive Discovery will establish pioneering At-211 capabilities in both regions, providing clients and collaborators with direct access to cutting-edge infrastructure.

These installations will enable:

  • Standardized, reproducible manufacturing of At-211 radiopharmaceuticals
  • A strong foundation for discovery, preclinical evaluation, and translational development
  • Scalable platforms suited for early research through to clinical manufacturing
  • The first commercial CRO environments with dedicated At-211 capabilities in both the UK and US

Atley and Perceptive intend to build a multi-phase partnership spanning equipment, services, and knowledge exchange. The shared goal is to enable the broader radiopharmaceutical sector to rapidly explore, validate, and advance new targeted alpha therapy candidates based on At-211 — one of the most promising radionuclides for next-generation precision oncology.

This partnership is expected to play a significant role in establishing robust At-211 infrastructure globally and in supporting biotech and pharmaceutical companies seeking access to specialized capabilities.

“At-211 is one of the most promising radionuclides for targeted radionuclide therapy, and Atley is at the forefront of At-211 innovation,” said Ben Murphy, CEO of Perceptive Discovery. “Through our partnership, the combination of Atley’s technology and our world-leading capabilities will accelerate the development of the next generation of radiopharmaceutical products.”

“This partnership with Perceptive Discovery represents a major step forward for the global At-211 ecosystem,” said Milton Lönnroth, CEO of Atley Solutions. “Perceptive Discovery is a global leader in radiopharmaceutical CRO services, and by equipping them with the Atley C100, we are enabling our joint customers to develop At-211-based radiopharmaceuticals faster and more efficiently. This marks the beginning of a long-term collaboration that will shape the field for years to come.”

About Atley Solutions
Atley Solutions is the global leader in commercial products and services for the development and manufacturing of At-211 radiopharmaceuticals. The Atley C100 is the world’s only commercial module for automated manufacturing of At-211 radiopharmaceuticals, addressing key challenges in radionuclide production and supply chain scalability. In addition to its cutting-edge technology, Atley provides radiopharmaceutical development services and targetry for At-211 manufacturing.

For more information, please visit www.atley.com 

About Perceptive
Perceptive Discovery delivers advanced preclinical and translational solutions that bridge scientific innovation to early-phase clinical success. With deep expertise in radiochemistry, in-vivo imaging, oncology and CNS models, dosimetry, assay development, and radioligand therapy, Perceptive Discovery provides integrated workflows that generate high-quality, decision-ready data for biotech and pharmaceutical partners worldwide.

For more information, please visit https://www.perceptive.com/about-perceptive-discovery 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/atley-and-perceptive-announce-strategic-collaboration-focused-on-astatine-211-302668994.html

SOURCE Perceptive Discovery

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Recovery extends to $88.20, momentum improves

Recovery extends to $88.20, momentum improves

The post Recovery extends to $88.20, momentum improves appeared on BitcoinEthereumNews.com. Silver price extended its recovery for the second straight day, up by
Share
BitcoinEthereumNews2026/02/05 07:34
Fed Decides On Interest Rates Today—Here’s What To Watch For

Fed Decides On Interest Rates Today—Here’s What To Watch For

The post Fed Decides On Interest Rates Today—Here’s What To Watch For appeared on BitcoinEthereumNews.com. Topline The Federal Reserve on Wednesday will conclude a two-day policymaking meeting and release a decision on whether to lower interest rates—following months of pressure and criticism from President Donald Trump—and potentially signal whether additional cuts are on the way. President Donald Trump has urged the central bank to “CUT INTEREST RATES, NOW, AND BIGGER” than they might plan to. Getty Images Key Facts The central bank is poised to cut interest rates by at least a quarter-point, down from the 4.25% to 4.5% range where they have been held since December to between 4% and 4.25%, as Wall Street has placed 100% odds of a rate cut, according to CME’s FedWatch, with higher odds (94%) on a quarter-point cut than a half-point (6%) reduction. Fed governors Christopher Waller and Michelle Bowman, both Trump appointees, voted in July for a quarter-point reduction to rates, and they may dissent again in favor of a large cut alongside Stephen Miran, Trump’s Council of Economic Advisers’ chair, who was sworn in at the meeting’s start on Tuesday. It’s unclear whether other policymakers, including Kansas City Fed President Jeffrey Schmid and St. Louis Fed President Alberto Musalem, will favor larger cuts or opt for no reduction. Fed Chair Jerome Powell said in his Jackson Hole, Wyoming, address last month the central bank would likely consider a looser monetary policy, noting the “shifting balance of risks” on the U.S. economy “may warrant adjusting our policy stance.” David Mericle, an economist for Goldman Sachs, wrote in a note the “key question” for the Fed’s meeting is whether policymakers signal “this is likely the first in a series of consecutive cuts” as the central bank is anticipated to “acknowledge the softening in the labor market,” though they may not “nod to an October cut.” Mericle said he…
Share
BitcoinEthereumNews2025/09/18 00:23
U.S. regulator declares do-over on prediction markets, throwing out Biden era 'frolic'

U.S. regulator declares do-over on prediction markets, throwing out Biden era 'frolic'

Policy Share Share this article 
Copy linkX (Twitter)LinkedInFacebookEmail
U.S. regulator declares do-over on prediction
Share
Coindesk2026/02/05 03:49